185 related articles for article (PubMed ID: 37889424)
1. Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.
Yan Z; Xu Y; Li K; Liu L
Acta Neurol Belg; 2024 Apr; 124(2):485-494. PubMed ID: 37889424
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.
Li Z; Tian M; Jia H; Li X; Liu Q; Zhou X; Li R; Dong H; Liu Y
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):197-206. PubMed ID: 37688479
[TBL] [Abstract][Full Text] [Related]
3. Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study.
Xia K; Klose V; Högel J; Huang T; Zhang L; Dorst J; Fan D; Ludolph AC
Eur J Neurol; 2023 Jul; 30(7):1899-1906. PubMed ID: 36999624
[TBL] [Abstract][Full Text] [Related]
4. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
5. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
6. Lipids, Apolipoproteins, Statins, and Intracerebral Hemorrhage: A Mendelian Randomization Study.
Yu Z; Zhang L; Zhang G; Xia K; Yang Q; Huang T; Fan D
Ann Neurol; 2022 Sep; 92(3):390-399. PubMed ID: 35655417
[TBL] [Abstract][Full Text] [Related]
7. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
8. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
9. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
[TBL] [Abstract][Full Text] [Related]
10. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
11. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
12. Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.
Yan Z; Xu Y; Li K; Liu L
Medicine (Baltimore); 2023 Sep; 102(39):e34690. PubMed ID: 37773823
[TBL] [Abstract][Full Text] [Related]
13. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
14. Mendelian Randomization Analysis Reveals Statins Potentially Increase Amyotrophic Lateral Sclerosis Risk Independent of Peripheral Cholesterol-Lowering Effects.
Wang W; Zhang L; Xia K; Huang T; Fan D
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239030
[TBL] [Abstract][Full Text] [Related]
15. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
Bi Y; Zhu Y; Tang S; Huang Y
J Headache Pain; 2023 Aug; 24(1):112. PubMed ID: 37596566
[TBL] [Abstract][Full Text] [Related]
16. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
17. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
18. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.
Jiang Z; Gu XJ; Su WM; Duan QQ; Yin KF; Ren YL; Wang Y; Cao B; Chen YP
Mol Neurobiol; 2024 Feb; ():. PubMed ID: 38324182
[TBL] [Abstract][Full Text] [Related]
20. Associations of the circulating levels of cytokines with risk of amyotrophic lateral sclerosis: a Mendelian randomization study.
Liu B; Lyu L; Zhou W; Song J; Ye D; Mao Y; Chen GB; Sun X
BMC Med; 2023 Feb; 21(1):39. PubMed ID: 36737740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]